MEI Pharma (MEIP)
NASDAQ:MEIP
Holding MEIP?
Track your performance easily

MEI Pharma (MEIP) Income Statement

997 Followers

MEI Pharma Income Statement

Last quarter (Q4 2024), MEI Pharma's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q4, MEI Pharma's net income was $-18.41M. See MEI Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Jun 24Jun 23Jun 22Jun 21Jun 20
Total Revenue
$ 65.30M$ 65.30M$ 48.82M$ 40.70M$ 34.80M$ 27.76M
Cost of Revenue
----$ 1.41M$ 2.67M
Gross Profit
$ 65.30M$ 65.30M$ 48.82M$ 40.70M$ 33.39M$ 25.09M
Operating Expense
$ 39.86M$ 39.86M$ 85.58M$ 116.18M$ 93.81M$ 50.78M
Operating Income
$ 14.54M$ 14.54M$ -36.76M$ -75.48M$ -60.42M$ -24.54M
Net Non Operating Interest Income Expense
--$ -3.35M$ -284.00K--
Other Income Expense
$ 7.66M$ 7.66M$ -4.93M$ 20.75M$ -19.12M$ 21.48M
Pretax Income
$ 17.78M$ 17.78M$ -31.84M$ -54.45M$ -41.31M$ -46.02M
Tax Provision
$ -796.00K$ -796.00K$ -187.00K$ -191.00K$ 8.00K$ 1.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ 17.78M$ 17.78M$ -31.84M$ -54.45M$ -41.31M$ -47.17M
Basic EPS
$ 2.67$ 2.67$ -4.78$ -8.80$ -9.00$ -10.20
Diluted EPS
$ 2.67$ 2.67$ -4.78$ -10.00$ -13.60$ -10.20
Basic Average Shares
$ 26.65M$ 6.66M$ 6.66M$ 6.22M$ 5.63M$ 4.55M
Diluted Average Shares
$ 26.65M$ 6.66M$ 6.66M$ 6.26M$ 5.72M$ 4.55M
Dividend Per Share
$ 1.75$ 1.75----
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 39.86M$ 39.86M$ 85.58M$ 116.18M$ 95.22M$ 53.45M
Net Income From Continuing And Discontinued Operation
$ 17.78M$ 17.78M$ -31.84M$ -54.45M$ -41.31M$ -47.17M
Normalized Income
$ 27.52M$ 27.88M-$ -54.65M$ -32.63M-
Interest Expense
------
EBIT
$ 15.02M$ 16.98M$ -32.02M$ -75.48M$ -60.42M$ -25.70M
EBITDA
$ 15.40M$ 17.36M$ -31.64M$ -75.16M$ -60.14M$ -25.59M
Currency in USD

MEI Pharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis